We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Pfizer, Moderna and AstraZeneca Release COVID-19 Vaccine Trial Blueprints

By HospiMedica International staff writers
Posted on 21 Sep 2020
Print article
Illustration
Illustration
Three vaccine makers, Pfizer Inc. (New York, NY, USA), AstraZeneca Cambridgeshire, England) and Moderna, Inc. (Cambridge, MA, USA), have released comprehensive road maps of their methods of evaluating their COVID-19 vaccines which are currently in trials.

The move aims to earn the trust of the public and scientists who have been demanding details of their studies, according to a report by The New York Times.

AstraZeneca is conducting trials of its adenovirus vector-based COVID-19 vaccine candidate, AZD1222, developed by the University of Oxford (Oxford, UK). Recently, AstraZeneca had confirmed that a participant in the Phase 3 trial of the company’s experimental COVID-19 vaccine candidate had developed a serious spinal inflammatory disorder, forcing it to halt the study which has now resumed. Pfizer and Biopharmaceutical New Technologies (BioNTech Mainz, Germany) are jointly developing a COVID-19 vaccine based on BioNTech’s proprietary mRNA technology and supported by Pfizer’s global vaccine development and manufacturing capabilities. Moderna is also conducting clinical trials of mRNA-1273, its mRNA vaccine candidate against COVID-19.

According to The New York Times report, the three companies have now revealed details of the methods for selection and monitoring of the trial participants, the conditions under which the trials could be halted early in case any problems arise, and the evidence to be used by researchers to gauge whether the participants who received the vaccines enjoy protection from COVID-19. Moderna also released a potential timetable which may extend to 2021 for determining whether its COVID-19 vaccine works, although Pfizer’s plan did not appear to include any estimated timeline for the availability of its trial results. Moderna’s study will involve 30,000 participants, while Pfizer’s trials will involve 44,000 participants.

According to AstraZeneca’s 111-page trial blueprint, known as a protocol, the company is aiming for a COVID-19 vaccine with 50% effectiveness. In order to determine if AstraZeneca’s vaccine trials have met that target, 150 volunteers who have been vaccinated or given placebo shots must be diagnosed with COVID-19, although the company has a safety board in place for carrying out an early analysis after only 75 cases are confirmed to have COVID-19. In case the vaccine demonstrates 50% effectiveness at that point, then AstraZeneca could end the trials early and apply for emergency use authorization to release the COVID-19 vaccine.

Such plans are not usually shared with the public, although vaccine makers are under increasing pressure to become more transparent about their methods of testing products, forcing them to abandon their traditional secrecy and release the comprehensive road maps of how their COVID-19 vaccines are being evaluated.

Related Links:
Pfizer Inc.
Biopharmaceutical New Technologies
AstraZeneca
University of Oxford
Moderna, Inc.


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Flocked Fiber Swabs
Puritan® patented HydraFlock®
New
Hospital Bed
Alphalite
New
Endoscopic Vessel Harvesting
VirtuoSaph Plus

Print article
Radcal

Channels

Critical Care

view channel
mage: The electroceutical epidermal patch is designed to inhibit bacterial growth (Photo courtesy of Saehyun Kim/University of Chicago)

Cutting-Edge Bioelectronic Device Offers Drug-Free Approach to Managing Bacterial Infections

Antibiotic-resistant infections pose an increasing threat to patient safety and healthcare systems worldwide. Recent estimates indicate that drug-resistant infections may rise by 70% by 2050, highlighting... Read more

Surgical Techniques

view channel
Image: Conceptual schematic showing microgrippers (µ-grippers) operating as biopsy tools in the upper urinary tract (Photo courtesy of Wangqu Liu, Yan Wan/Gracias Lab, Johns Hopkins University)

Microgrippers For Miniature Biopsies to Create New Cancer Diagnostic Screening Paradigm

The standard diagnosis of upper urinary tract cancers typically involves the removal of suspicious tissue using forceps, a procedure that is technically challenging and samples only a single region of the organ.... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more